vaclav-volrab-shutterstock-com-leap-

Vaclav Volrab / Shutterstock.com

6 December 2016AmericasKaren Mangasarian and Ryan Murphey

Life sciences transactions: look before you leap

Whether it is to replenish innovator pharmaceutical companies’ diminishing new product pipelines or because of the allure of new platform technologies, the life sciences industry has been an active sector for transactions of various kinds.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

USPTO clarifies AI's role in patent eligibility